Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2025-11-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于公司及子公司开展外汇套期保值业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Yunnan Watson Biotechnology Co., Ltd. regarding the company's and its subsidiaries' engagement in foreign exchange hedging business. It details the purpose, transaction types, amounts, risk analysis, approval procedures, and accounting policies related to the foreign exchange hedging activities. The document includes board and audit committee meeting approvals but does not contain financial statements or detailed financial performance data. It is a regulatory announcement about a financing-related activity (foreign exchange hedging) rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the company's financing risk management activities and related authorizations.
2025-11-28 Chinese
关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice for the convening of the 2025 first extraordinary general meeting of shareholders of Yunnan Watson Biotechnology Co., Ltd. It includes details about the meeting time, location, agenda items, voting procedures, and registration requirements. The content focuses on informing shareholders about the meeting and the proposals to be voted on, including profit distribution, related party transactions, appointment of auditors, and amendments to company bylaws. There are no financial statements or detailed financial analysis present, nor is this a transcript or a report of voting results. The document is a formal announcement of the meeting itself, not the meeting materials or results. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-11-28 Chinese
公司章程（2025年11月）
Governance Information Classification · 100% confidence The document is titled "公司章程" which translates to "Company Articles of Association" or "Company Bylaws." It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, and other governance-related rules. It references legal frameworks such as the Company Law of the People's Republic of China and securities regulations. The content is focused on the internal rules and governance structure of the company rather than financial performance, audit results, or announcements. It is a comprehensive governance document that sets out the company's internal rules and board structure. Therefore, the document fits the category of Governance Information (CGR).
2025-11-28 Chinese
关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from Yunnan Watson Biotechnology Co., Ltd. regarding revisions to the company's Articles of Association (公司章程). It discusses changes in corporate governance, shareholder rights, board responsibilities, and compliance with updated laws and regulations. The content is focused on governance structure and internal rules rather than financial results or operational performance. There is no indication that this is a full annual report, audit report, or financial statement. It is not a brief announcement or a notice of voting results but a substantive governance-related document. Therefore, the document best fits the category of Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2025-11-28 Chinese
累积投票制实施细则（2025年11月）
Governance Information Classification · 95% confidence The document is titled '累积投票制实施细则' which translates to 'Cumulative Voting System Implementation Rules' for the company 云南沃森生物技术股份有限公司. It details the rules and procedures for cumulative voting in the election of directors, including nomination, voting principles, election principles, and special procedures. The content focuses on governance practices related to board elections and shareholder voting rights, rather than financial results, audit opinions, or regulatory announcements. It is a governance-related document outlining internal rules and procedures for board elections, which fits the definition of Governance Information (CGR). The document is not an announcement or a brief notice but a detailed set of rules, so it is not RPA or RNS. Therefore, the appropriate classification is CGR with high confidence.
2025-11-28 Chinese
关于受让控股子公司少数股权并与汇祥越泰（天津）投资合伙企业（有限合伙）签署《股权转让协议》的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about the company (云南沃森生物技术股份有限公司) acquiring minority equity in its controlled subsidiary 玉溪沃森生物技术有限公司 by purchasing shares from another investor. It includes transaction background, board resolutions, equity structure, financial data of the subsidiary, terms of the equity transfer agreement, payment schedule, risk disclosures, and authorization details. The document is a formal public announcement of a capital transaction involving share acquisition in a subsidiary, with no indication that it is a full financial report, earnings release, or management discussion. It is not a merger or acquisition of the entire company, but a capital/financing update related to shareholding changes in a subsidiary. The document length is over 6,000 characters and contains substantive transaction details. Therefore, the best fitting category is Capital/Financing Update (CAP).
2025-11-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.